Physician profile
Robert S Smith
NPI 1154386639
$3,716.38
in general payments reported to CMS, 2019-2025
26 companies · $1,456 in 2025
The $1,456 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $674 · 2020: $78.43 · 2021: $11.50 · 2022: $50.64 · 2023: $362 · 2024: $1,084 · 2025: $1,456.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,880 · Education: $22.10.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,879.62 |
| Education | $22.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $836.98 | 2019-2025 | Skyrizi, Rinvoq, Creon |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $357.64 | 2019-2025 | Xifaxan, Trulance |
| Madrigal Pharmaceuticals | $234.27 | 2024-2025 | Rezdiffra |
| Medtronic, INC. | $230.10 | 2023-2025 | Interstim |
| Ardelyx, INC. | $224.44 | 2023-2025 | Ibsrela |
| Janssen Scientific Affairs, LLC | $214.92 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $201.52 | 2019-2025 | Entyvio |
| Janssen Biotech, INC. | $187.03 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Procept Biorobotics Corporation | $157.26 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $141.65 | 2024-2025 | Dupixent |
| Genzyme Corporation | $127.68 | 2025 | |
| Phathom Pharmaceuticals, INC. | $121.17 | 2024-2025 | Voquezna |
| Lilly USA, LLC | $116.66 | 2024-2025 | Omvoh |
| Sandoz INC. | $114.92 | 2024-2025 | Hyrimoz |
| Celltrion USA INC. | $98.44 | 2024-2025 | Vegzelma, Zymfentra |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $93.41 | 2019-2024 | |
| Ipsen Biopharmaceuticals, INC | $49.39 | 2025 | Iqirvo |
| Braintree Laboratories, INC. | $37.70 | 2024-2025 | Sutab, Suflave |
| Qol Medical, LLC | $36.49 | 2024 | Sucraid |
| Exact Sciences Corporation | $31.68 | 2024 | Cologuard Collection Kit |
| Organon LLC | $21.86 | 2024 | |
| Mirum Pharmaceuticals, INC. | $21.64 | 2025 | Livmarli |
| Intercept Pharmaceuticals, INC. | $19.00 | 2024 | |
| Daiichi Sankyo INC. | $14.58 | 2019 | |
| Boston Scientific Corporation | $13.45 | 2020 | |
| Pfizer INC. | $12.50 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.